Atopic Dermatitis Clinical Trials Market

Atopic Dermatitis Clinical Trials Market Size by Phase (Phase I, Phase II, Phase III, Phase IV), Molecule Type (Large Molecules, Small Molecules), Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2024 to 2033

Base Year: 2023 Historical Data: 2020-22
  • Report ID: TBI-14047
  • Published Date: Jan, 2024
  • Pages: 237
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

The global atopic dermatitis clinical trials market was valued at USD 2.85 Billion in 2023, which is anticipated to grow at a CAGR of 12.73% from 2024 to 2033. The drivers propelling the market expansion include technological advancements, an increase in the prevalence of atopic dermatitis, a growing pipeline of therapies for treating the ailment, and an increase in funding and investments. In addition, partnerships between dermatological and pharmaceutical firms and contract research organisations facilitate knowledge exchange, expedited product development, and risk reduction, all of which contribute to the expansion of the market.

Market Introduction:

Millions of people worldwide suffer from atopic dermatitis, sometimes referred to as eczema, which is characterised by itching, redness, and inflammation of the skin. The intricacy of this ailment has led to extensive research activities aimed at discovering effective treatments and remedies. An emerging trend in the market for clinical trials for atopic dermatitis is the growing emphasis on immunomodulatory treatments. With the goal of developing more specialised and effective treatments, trials are currently investigating novel medications that target particular immunological pathways implicated in the pathophysiology of Atopic Dermatitis. Biologics are becoming more and more popular; clinical trials are being conducted to determine the effectiveness of biopharmaceuticals such as monoclonal antibodies. By addressing underlying immune system dysregulation, these biologics offer a promising new approach to the treatment of mild to severe Atopic Dermatitis. Customising care to each patient's unique profile is becoming more and more popular. Personalised medicine techniques are finding their way into clinical trials more and more, taking patient-specific variables, biomarkers, and genetic predispositions into account to maximise therapeutic benefits and reduce adverse effects. Advanced topical preparations that provide tailored therapy for localised symptoms of Atopic Dermatitis are being researched. More choices for treating milder types of the illness may be provided by these formulations, which may contain new corticosteroids, calcineurin inhibitors, or barrier repair agents. Clinical trials are collecting data and engaging patients more efficiently because of the incorporation of telemedicine and remote monitoring. This development improves trial efficiency while also reflecting a larger trend towards digital healthcare solutions, which could have an impact on how Atopic Dermatitis is treated in the future. Paediatric populations are receiving a lot of attention in clinical trials due to the increasing frequency of Atopic Dermatitis in children. In order to ensure that treatment plans are secure and efficient for this susceptible patient population, this trend attempts to address the particularities of paediatric Atopic Dermatitis.

Atopic Dermatitis Clinical Trials Market Size

Get an overview of this study by requesting a free sample

Recent Development
  • ADORING 1, a second Phase 3 research assessing the safety and effectiveness of VTAMA (tapinarof) cream, 1%, for moderate to severe atopic dermatitis in adults and paediatric participants as young as 2 years old, was reported to have shown promising results by Sciences in May 2023. The experiment was double-blind and randomised.
  • Positive results from the DELTA 1 pivotal phase 3 clinical trial, which evaluated the topical pan-Janus kinase (JAK) inhibitor delgocitinib cream, were revealed by LEO Pharma in March 2023. The experiment was designed to evaluate the drug's potential for treating adults with moderate to severe chronic hand eczema (CHE).
  • The U.S. Food and Drug Administration (FDA) approved Pfizer's CIBINQO (abrocitinib) in January 2022 for the treatment of people with moderate-to-severe atopic dermatitis.

Market Dynamics:


Rising incidence of atopic dermatitis worldwide- The market for clinical trials for atopic dermatitis is expanding due to a number of important considerations. First and foremost, there is a greater need for effective therapeutic solutions due to the rising global frequency of Atopic Dermatitis, which has prompted increased research and development efforts. Furthermore, discoveries about the complex immunological and genetic components of Atopic Dermatitis have opened the door to the investigation of tailored, precision treatments. A more advanced and successful approach to managing atopic dermatitis has been fostered by the expanding trend towards personalised medicine, which has increased interest in customising medications to specific patient profiles. Furthermore, the strong partnerships among biotech businesses, research institutes, and pharmaceutical corporations have stimulated creativity and led to the identification and creation of new therapeutic treatments. The focus on comparative effectiveness research encourages competition, which in turn promotes the development of better and unique therapy choices while also improving current treatment regimens. The market for clinical trials for atopic dermatitis is expected to increase steadily as a result of these variables working together, providing opportunities for improved patient care and results.

Regional segmentation analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America emerged as the most significant global atopic dermatitis clinical trials market, with a 36.07% market revenue share in 2023. One of the main regions driving the expansion of the atopic dermatitis clinical trials market is North America. Numerous pharmaceutical and dermatological firms are based in this region, and they are helping the market grow by contracting out some of their development efforts to service providers. In North America, the United States had the biggest market share. There are a lot of people living in the United States, and many of them suffer from atopic dermatitis. Large patient pools are desirable for clinical trials, particularly ones that call for a variety of participant demographics. The United States has a strong infrastructure for research, encompassing research institutes, academic medical centres, and established clinical trial locations. Because of this infrastructure, clinical trials can be conducted more effectively, which attracts sponsors and investigators and helps the area establish a competitive edge.

North America Region Atopic Dermatitis Clinical Trials Market Share in 2023 - 36.07%

Check the geographical analysis of this market by requesting a free sample

Phase Segment Analysis

The phase segment is divided into phase I, phase II, phase III, and phase IV. The phase II segment dominated the market, with a market share of around 27.65% in 2023. The rising number of medications undergoing phase II studies is primarily responsible for the high category shares. Furthermore, phase II trial development comes at a hefty expense. As a result, there is a significant increase in investment throughout these stages, supporting high segment shares. Large sums of money are also being invested by a number of pharmaceutical companies in the clinical development of these medications. For example, Triventi Bio received USD 92 million in Series A funding in October 2023 to advance TRIV-509, its core antibody programme, into clinical development. TRIV-509 is currently in pre-clinical development, and it is expected that the money will support it through the Phase IIa clinical trial.

Molecule Type Segment Analysis

The molecule type segment is divided into large molecules, and small molecules. The large molecules segment dominated the market, with a market share of around 62.49% in 2023. This high percentage can be linked to the global rise in atopic dermatitis and skin eczema occurrence, which is driving up demand for biologics. To treat the illness, a number of biopharmaceutical companies are growing their treatments pipeline. For example, according to a 2022 article published by Springer Nature Limited, in addition to receiving regulatory approval for biologics like the JAK1/2 inhibitor baricitinib, the IL-4Ra inhibitor dupilumab, and the anti-IL-13 inhibitor tralokinumab in Europe, more than 70 new compounds are being developed for the treatment of mild to severe atopic dermatitis. Therefore, the main driver of the segment's strong shares and profitable growth rate during the projection period is the expanding pipeline of products under large molecules.

Some of the Key Market Players:
  • Imavita
  • Oncodesign services
  • Redoxis
  • Hooke Laboratories, LLC
  • Charles River Laboratories
  • Syneos Health
  • Novotech
Report Description:
Attribute Description
Market Size Revenue (USD Billion)
Market size value in 2023 USD 2.85 Billion
Market size value in 2033 USD 9.44 Billion
CAGR (2024 to 2033) 12.73%
Historical data 2020-2022
Base Year 2023
Forecast 2024-2033
Region The regions analyzed for the market are Asia Pacific, Europe, South America, North America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
Segments Phase, Molecule Type

Frequesntly Asked Questions

As per The Brainy Insights, the size of the atopic dermatitis clinical trials market was valued at USD 2.85 Billion in 2023 & USD 9.44 Billion by 2033.

Global atopic dermatitis clinical trials market is growing at a CAGR of 12.73% during the forecast period 2024-2033.

North America region emerged as the largest market for the atopic dermatitis clinical trials.

Rising incidence of atopic dermatitis worldwide is a significant driving factor for the growth of the atopic dermatitis clinical trials market.

Key players are Imavita, Oncodesign services, QIMA LTD, Redoxis, Hooke Laboratories, LLC, Charles River Laboratories, BIOCYTOGEN, Syneos Health, REPROCELL Inc., Novotech, among others.

Request Table of Content


This study forecasts revenue at global, regional, and country levels from 2020 to 2033. The Brainy Insights has segmented the global atopic dermatitis clinical trials market based on below mentioned segments:

Global Atopic Dermatitis Clinical Trials by Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Global Atopic Dermatitis Clinical Trials by Molecule Type:

  • Large Molecules
  • Small Molecules

Global Atopic Dermatitis Clinical Trials by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa


Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:


Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights


Free Customization


Fortune 500 Clients


Free Yearly Update On Purchase Of Multi/Corporate License


Companies Served Till Date